TableĀ 1 Clinical and pathological data for patients associated with ypN status
| Ā | ypN0 Nā=ā139 | ypN1 Nā=ā50 | ypN2 Nā=ā32 | ypN3a Nā=ā25 | ypN3b Nā=ā12 | p.overall |
|---|---|---|---|---|---|---|
Gender | Ā | Ā | Ā | Ā | Ā | 0.886 |
āF | 40 (28.8%) | 16 (32.0%) | 9 (28.1%) | 8 (32.0%) | 5 (41.7%) | Ā |
āM | 99 (71.2%) | 34 (68.0%) | 23 (71.9%) | 17 (68.0%) | 7 (58.3%) | Ā |
Age | Ā | Ā | Ā | Ā | Ā | 0.778 |
āā¤ā60 | 44 (31.7%) | 17 (34.0%) | 10 (31.2%) | 8 (32.0%) | 6 (50.0%) | Ā |
ā>ā60 | 95 (68.3%) | 33 (66.0%) | 22 (68.8%) | 17 (68.0%) | 6 (50.0%) | Ā |
TRG | ||||||
ā0 | 32 (23.0%) | 4 (8.00%) | 1 (3.12%) | 0 (0.00%) | 0 (0.00%) | Ā |
ā1 | 39 (28.1%) | 4 (8.00%) | 3 (9.38%) | 0 (0.00%) | 2 (16.7%) | Ā |
ā2 | 38 (27.3%) | 24 (48.0%) | 10 (31.2%) | 11 (44.0%) | 5 (41.7%) | Ā |
ā3 | 30 (21.6%) | 18 (36.0%) | 18 (56.2%) | 14 (56.0%) | 5 (41.7%) | Ā |
ypT | ||||||
āT0 | 32 (23.0%) | 4 (8.00%) | 1 (3.12%) | 0 (0.00%) | 0 (0.00%) | Ā |
āT1 | 28 (20.1%) | 9 (18.0%) | 1 (3.12%) | 0 (0.00%) | 0 (0.00%) | Ā |
āT2 | 31 (22.3%) | 6 (12.0%) | 4 (12.5%) | 1 (4.00%) | 0 (0.00%) | Ā |
āT3 | 32 (23.0%) | 20 (40.0%) | 19 (59.4%) | 13 (52.0%) | 2 (16.7%) | Ā |
āT4a | 15 (10.8%) | 11 (22.0%) | 6 (18.8%) | 11 (44.0%) | 9 (75.0%) | Ā |
āT4b | 1 (0.72%) | 0 (0.00%) | 1 (3.12%) | 0 (0.00%) | 1 (8.33%) | Ā |
ypStage | ||||||
āpCR | 28 (20.1%) | 0 (0.00%) | 0 (0.00%) | 0 (0.00%) | 0 (0.00%) | Ā |
āypT0Nā+ā | 0 (0.00%) | 4 (8.00%) | 1 (3.12%) | 0 (0.00%) | 0 (0.00%) | Ā |
āypStage I | 62 (44.6%) | 9 (18.0%) | 0 (0.00%) | 0 (0.00%) | 0 (0.00%) | Ā |
āypStage II | 47 (33.8%) | 24 (48.0%) | 5 (15.6%) | 0 (0.00%) | 0 (0.00%) | Ā |
āypStage III | 2 (1.44%) | 13 (26.0%) | 26 (81.2%) | 25 (100%) | 12 (100%) | Ā |
Size(cm) | Ā | Ā | Ā | Ā | Ā | ā<ā0.001 |
āā¤ā5 | 128 (92.1%) | 43 (86.0%) | 23 (71.9%) | 14 (56.0%) | 3 (25.0%) | Ā |
ā>ā5 | 11 (7.91%) | 7 (14.0%) | 9 (28.1%) | 11 (44.0%) | 9 (75.0%) | Ā |
Location | ||||||
āDiffuse | 3 (2.16%) | 1 (2.00%) | 1 (3.12%) | 0 (0.00%) | 1 (8.33%) | Ā |
āLower | 71 (51.1%) | 26 (52.0%) | 16 (50.0%) | 11 (44.0%) | 6 (50.0%) | Ā |
āMiddle | 35 (25.2%) | 11 (22.0%) | 11 (34.4%) | 12 (48.0%) | 5 (41.7%) | Ā |
āUpper | 30 (21.6%) | 12 (24.0%) | 4 (12.5%) | 2 (8.00%) | 0 (0.00%) | Ā |
Differentiation | ||||||
āHigh | 5 (3.60%) | 2 (4.00%) | 0 (0.00%) | 0 (0.00%) | 0 (0.00%) | Ā |
āMiddle | 49 (35.3%) | 21 (42.0%) | 16 (50.0%) | 8 (32.0%) | 1 (8.33%) | Ā |
āPoor | 61 (43.9%) | 24 (48.0%) | 15 (46.9%) | 15 (60.0%) | 11 (91.7%) | Ā |
āUnknown | 24 (17.3%) | 3 (6.00%) | 1 (3.12%) | 2 (8.00%) | 0 (0.00%) | Ā |
Neoadjuvant | ||||||
āSOX | 99 (71.2%) | 34 (68.0%) | 25 (78.1%) | 13 (52.0%) | 5 (41.7%) | Ā |
āXELOX | 25 (18.0%) | 8 (16.0%) | 3 (9.38%) | 5 (20.0%) | 5 (41.7%) | Ā |
āFOLFOX | 7 (5.04%) | 6 (12.0%) | 3 (9.38%) | 3 (12.0%) | 2 (16.7%) | Ā |
āELSE | 8 (5.76%) | 2 (4.00%) | 1 (3.12%) | 4 (16.0%) | 0 (0.00%) | Ā |
Post-operative adjuvant therapy | Ā | Ā | Ā | Ā | Ā | 0.740 |
āYes | 118 (84.9%) | 43 (86.0%) | 30 (93.8%) | 21 (84.0%) | 10 (83.3%) | Ā |
āNo | 21 (15.1%) | 7 (14.0%) | 2 (6.25%) | 4 (16.0%) | 2 (16.7%) | Ā |
Combined immunotherapy | Ā | Ā | Ā | Ā | Ā | 0.175 |
āYes | 24 (17.3%) | 6 (12.0%) | 5 (15.6%) | 6 (24.0%) | 5 (41.7%) | Ā |
āNo | 115 (82.7%) | 44 (88.0%) | 27 (84.4%) | 19 (76.0%) | 7 (58.3%) | Ā |